Hijazi Ziyad M, Kenny Damien
1Sidra Cardiac Program,Sidra Medical & Research Center,Doha,Qatar.
3Our Lady's Children's Hospital,Dublin,Ireland.
Cardiol Young. 2017 Dec;27(10):1974-1985. doi: 10.1017/S1047951117002141.
CHD affects millions of patients worldwide. Interventional therapies for CHD goes back to the mid-1960s when Bill Rashkind performed balloon atrial septostomy on a cyanotic baby with transposition of the great vessels. This was followed by development of balloon catheters to perform balloon valvuloplasties and angioplasties in the early to late 1980s. Although King and Mills performed the first transcatheter closure of secundum atrial septal defect in the mid-1970s, this procedure was better realised in the mid-1990s. More intracardiac defect closures were performed in the late 1990s and early 2000. This brings us to the current era of percutaneous valve implantation as developed by Bonhoeffer. In this paper, we will discuss the past, present, and future of interventional cardiac catheterisation for CHD patients.
冠心病影响着全球数百万患者。冠心病的介入治疗可追溯到20世纪60年代中期,当时比尔·拉什金德为一名患有大血管转位的青紫婴儿实施了球囊房间隔造口术。随后在20世纪80年代早期至晚期,开发了用于进行球囊瓣膜成形术和血管成形术的球囊导管。尽管金和米尔斯在20世纪70年代中期首次进行了继发孔房间隔缺损的经导管封堵术,但该手术在20世纪90年代中期才得到更好的实现。20世纪90年代末和21世纪初进行了更多的心内缺损封堵术。这就将我们带入了由邦霍费尔开创的经皮瓣膜植入的当前时代。在本文中,我们将讨论冠心病患者介入心脏导管术的过去、现在和未来。